Endpoints News· @endpts · X·· 1 天前精选AI 评分70
AI 导读
阿斯利康将投资20亿美元获得Summit 12%的股权，而非此前据报考虑过的ivonescimab整体交易。该交易使阿斯利康以持股方式押注这款肿瘤药物。原文链接：https://endpoints.news/astrazeneca-buys-a-2b-stake-in-summit-taking-equity-in-bet-on-cancer-drug/
推荐理由
阿斯利康以20亿美元入股Summit 12%，读者可据此观察其对ivonescimab权益的取舍逻辑。
正文
AstraZeneca is investing $2B for a 12% slice of Summit instead of the full ivonescimab deal it reportedly weighed last year. https://endpoints.news/astrazeneca-buys-a-2b-stake-in-summit-taking-equity-in-bet-on-cancer-drug/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=
来源：Endpoints News · x.com